EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study

Mira M Liu, Octavia Bane, Xin Mu, Haitham Al-Mubarak, Ghadi Abboud, Arthi M Reddy, Paul Kennedy, Philip Robson, Kirolos Meilika, Laura Zuluaga, Amir Horowitz, Bernd Kuhn und 6 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012833 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Mira M Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Kidney Neoplasms, Multiparametric Magnetic Resonance Imaging, Magnetic Resonance Imaging. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Center for Advancing Translational Sciences, Bayer HealthCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Preoperative characterization of renal mass malignancy, subtype, and immuno-oncologic pathology could inform and improve tailored management decisions. We examine multiparametric MRI (mpMRI) for (1) sensitivity to immuno-oncologic markers of the tumor immune microenvironment and (2) classification of tumor malignancy, subtype, and grade. Methods and materials In a prospective, institutional review board-approved single-center study, 40 patients (13 female/27 males, 60.4±10.7 years) scheduled to undergo surgical management of solid renal masses underwent preoperative 1.5T MRI. This included T1, multi-b-value diffusion-weighted imaging (DWI as intravoxel incoherent motion (IVIM), and apparent diffusion coefficient (ADC)), R2*, arterial spin labeling (ASL), and dynamic contrast-enhanced (DCE-)MRI. Clear cell likelihood scores (ccLS) were assigned using clinical MR images. Tumor diagnoses were extracted from the surgical histopathology. Logistic regression models were built with leave-one-out cross-validation and bootstrapping. Interobserver measurements were obtained in a subset of 27 patients, and tests–retests were run for 2 patients. Tumors from 18 patients with clear cell renal cell carcinoma (ccRCC) underwent immunohistochemistry for CD3, CD4, CD8, CD68, PD-L1, NKp46, HIF-1α, and CD31. MR biomarkers of immunohistochemistry stains were identified with Pearson’s r correlation, and diagnostic OR for >5% or >15% cells stained positive, by cross-validated univariate logistic regression.

Results

Of the 40 solid renal masses (mean (range)=32 (8–68) mm), 22 were clear cell, 9 non-clear cell and 9 benign, with 10 Grade 1. IVIM f, D*, and fD* correlated with T cells (CD4, CD3, CD8), while R2* correlated positively with macrophage presence (CD68) and negatively with angiogenesis (CD31). DCE-MRI and ASL negatively correlated with CD68. ASL negatively correlated with CD8 T cells. IVIM D* returned a significant OR for CD68-positive stains (OR=55.0, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsMultiparametric Magnetic Resonance ImagingMagnetic Resonance ImagingHumansMaleFemaleMiddle AgedPilot ProjectsAgedProspective StudiesTumor MicroenvironmentAdultBiomarkers, Tumor

Stichwörter der Autor:innen

BiomarkerKidney CancerPathologyTumor microenvironment - TMEfMRI / PET

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Diagnostic, Molecular and Interventional Radiology, Mount Sinai Hospital, New York, New York, USA.
  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Siemens Healthineers AG, Erlangen, BY, Germany.
  • Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Förderung

  • National Center for Advancing Translational Sciences
  • Bayer HealthCare

Zitieren

APA

Liu, M. M., Bane, O., Mu, X., Al-Mubarak, H., Abboud, G., Reddy, A. M., Kennedy, P., Robson, P., Meilika, K., Zuluaga, L., Horowitz, A., Kuhn, B., Thin, T. H., Garcia-Barros, M., Brody, R., Badani, K., Taouli, B., & Lewis, S. (2025). Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012833

Vancouver

Liu MM, Bane O, Mu X, Al-Mubarak H, Abboud G, Reddy AM, et al. Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012833

BibTeX
@article{Liu2025,
  author = {Liu, Mira M and Bane, Octavia and Mu, Xin and Al-Mubarak, Haitham and Abboud, Ghadi and Reddy, Arthi M and Kennedy, Paul and Robson, Philip and Meilika, Kirolos and Zuluaga, Laura and Horowitz, Amir and Kuhn, Bernd and Thin, Tin Htwe and Garcia-Barros, Monica and Brody, Rachel and Badani, Ketan and Taouli, Bachir and Lewis, Sara},
  title = {Immuno-oncologic profiling of renal masses using multiparametric MRI: a pilot study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012833}
}
Kostenlos starten →